Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
09 Januar 2024 - 5:15PM
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 9 January 2024 — This
company announcement discloses the data of the transaction(s) made
in Novo Nordisk shares by the company’s board members, executives
and their associated persons in accordance with Article 19 of
Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Liselotte Hyveled |
2 |
Reason for the notification |
a) |
Position/status |
Member of the Board of Directors. |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
Identification code |
Novo Nordisk B DK0062498333 |
b) |
Nature of the transaction |
Transfer of shares |
c) |
Price(s) and volume(s) |
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
DKK 683.90 |
1,420 shares |
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
1,420 sharesDKK 971,138.00 |
e) |
Date of the transaction |
2023-11-03 |
f) |
Place of the transaction |
Outside a trading venue |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Maha Kutay |
2 |
Reason for the notification |
a) |
Position/status |
Closely associated person to Kasim Kutay, member of the Board of
Directors. |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
Identification code |
Novo Nordisk B DK0060534915 |
b) |
Nature of the transaction |
Purchase of shares |
c) |
Price(s) and volume(s) |
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
DKK 1,098.66 |
14 shares |
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
14 sharesDKK 15,381.20 |
e) |
Date of the transaction |
2023-04-12 |
f) |
Place of the transaction |
Nasdaq Copenhagen |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Maha Kutay |
2 |
Reason for the notification |
a) |
Position/status |
Closely associated person to Kasim Kutay, member of the Board of
Directors. |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
Identification code |
Novo Nordisk B DK0060534915 |
b) |
Nature of the transaction |
Purchase of shares |
c) |
Price(s) and volume(s) |
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
DKK 1,370.44 |
3 shares |
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
3 sharesDKK 4,111.33 |
e) |
Date of the transaction |
2023-09-12 |
f) |
Place of the transaction |
Nasdaq Copenhagen |
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 61,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Elizabeth
DeLuca (US)+1 609 580 9868edel@novonordisk.com |
Investors: |
|
Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer +45 3079 6656 azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company announcement No 3 / 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024